查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861573

周边动脉疾病治疗市场依产品类型、适应症、最终用户及给药途径划分－2025-2032年全球预测

Peripheral Arterial Disease Therapeutics Market by Product Type, Indication, End User, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，周边动脉疾病治疗市场将成长至 103 亿美元，复合年增长率为 9.06%。

关键市场统计数据
基准年 2024 51.4亿美元
预计年份：2025年 56亿美元
预测年份 2032 103亿美元
复合年增长率 (%) 9.06%

周边动脉疾病药物的全面概述：影响治疗路径和相关人员决策的临床、营运和商业性因素框架

周边动脉疾病涉及血管病理学、治疗方法创新和不断变化的医疗服务模式等许多复杂因素。本执行摘要综合了多学科的证据，阐明了临床实践、法规环境和商业策略之间的交集。以下重点介绍从传统药物治疗到器械介入治疗的各种治疗方法，并将这些进展置于医疗系统优先事项和以患者为中心的治疗结果的背景下进行说明。

肢体缺血和间歇性跛行的临床负担持续推动对现有药物和新一代治疗方法的需求。因此，临床医生和支付方越来越重视从手术疗效、长期肢体挽救和心血管风险降低等方面评估干预措施。此外，患者的治疗流程通常包括门诊护理路径、综合创伤护理以及血管团队协作，这些流程强调功能恢復和生存指标。鑑于这些现实情况，相关人员必须整合临床证据、操作可行性和不断变化的报销模式，以优化治疗方法的应用和患者预后。

程序创新、药物进步和数位化诊疗路径如何共同重新定义周边动脉疾病的治疗标准和长期管理

临床实务与科技的融合正在改变周边动脉疾病的诊断、治疗和管理方式。影像学、导管介入术和辅助器械的最新进展推动了微创血管内治疗技术的快速发展。同时，人们也重新关注药物治疗策略，不再只限于缓解症状，而是致力于降低重大心血管事件的发生率，进而重塑了不同医疗机构的治疗目标。

同时，数位医疗和远端监测正在变革术后追踪和慢性病管理。远端医疗支援的血管诊所和穿戴式动态血流监测设备与传统血管实验室相辅相成，能够早期发现病情恶化并提供个人化復健方案。此外，再生医学和生物目标的临床研发正在加速推进，并有望为再灌注治疗选择有限的患者开闢新的治疗途径。最后，某些手术的治疗越来越多地在门诊进行，这提升了门诊手术中心和专科诊所作为医疗服务场所的策略重要性。这些因素共同推动着以价值、病患体验和长期疗效为优先的整合式医疗模式的发展。

预计随着2025年美国关税调整重塑治疗生态系统的成本结构和业务永续营运，供应链调整、筹资策略和产品设计都将发生变化。

预计美国2025年关税政策的变化可能会影响周边动脉疾病治疗生态系统的多个环节，相关人员已开始为各种连锁反应做好准备。对进口医疗设备、药品和中间组件征收关税可能会增加特种导管、药物释放型球囊和诊断成像设备等设备的到岸成本。因此，製造商和医疗系统可能会重新评估筹资策略，并寻求透过使用替代供应商、近岸外包和加快生产本地化来降低风险。

此外，关税还可能影响医院和门诊手术中心的供应链时序和库存策略。短期内，采购部门可能会增加缓衝库存或重新谈判供应合同，以确保关键耗材的稳定供应。长期来看，製造商可能会重新评估定价模式或迁移製造地，这将影响采购週期和设施升级的资本规划。从研发角度来看，关税带来的成本压力可能会促使投资重点转向高效节能的技术和采用抗关税组件的模组化设备设计。最后，监管机构和支付方的应对措施也将不断调整，以确保医疗服务的可负担性和可及性，并促进各方合作，在不降低临床标准的倡议，维持医疗服务的连续性。

整合产品子类别、临床适应症、医疗服务管道和给药途径等因素的策略性细分洞察，对于指导产品开发和商业化选择至关重要。

深入了解患者、产品和通路细分对于协调研发和商业化策略至关重要。产品类型涵盖抗凝血剂、抗血小板药物、溶栓剂和血管扩张剂。抗凝血剂又细分为直接口服抗凝血剂、肝素和Warfarin；抗血小板药物包括阿斯匹灵、Clopidogrel和替格瑞洛；溶栓剂包括组织型胞浆素原原激活剂 (t-PA) 和尿激酶；血管扩张剂则以Cilostazol和Pentoxifylline碱为代表。这些差异会影响临床决策、处方集安排和术后管理，因为每个亚类药物都具有独特的动态、监测要求和交互作用特征。

基于适应症的分类区分了严重肢体缺血和间歇性跛行，二者在疾病进程、治疗紧迫性和多学科协作需求方面存在显着差异。终端使用者管道涵盖门诊手术中心、医院和专科诊所，而地点选择会影响设备选择、人员配备模式、报销途径和住院时长。此外，给药途径（口服或肠外给药）也与依从性、门诊可行性以及监测和给药的资源分配等因素密切相关。整合这些细分维度，有助于相关人员优先考虑临床开发项目、优化讯息，并制定能够满足临床医生、支付方和患者不同需求的准入策略。

美洲、欧洲、中东和非洲以及亚太地区的区域特征和战略意义，决定了监管方法、证据要求和进入策略。

区域趋势对临床实践、监管预期和供应链结构有着深远的影响。在美洲，临床指引日益强调在关注肢体介入的同时，也要注重综合性的心血管风险降低；而医疗系统则需要在专科医生数量和不断增长的门诊手术量之间寻求平衡。此外，该地区的支付模式也存在显着差异，这影响着新型治疗方法的可及性和纳入健保处方笺的时间。因此，优先考虑真实世界证据生成和以支付方为中心的卫生经济学论证的策略，将在商业性谈判中获得支持。

在欧洲、中东和非洲地区，监管协调和多样化的报销途径正在影响打入市场策略和临床应用率。在许多市场，监管机构强调长期治疗效果和成本效益数据，这延长了疗法广泛应用的时间，同时也为那些能够保肢和改善心血管功能的治疗方法创造了可持续的价值提案。同时，亚太市场的特点是微创手术的快速普及、介入治疗能力的不断提升以及强劲的本土製造雄心，这些因素共同影响着定价动态和伙伴关係模式。了解这些区域特征有助于申办方合理安排市场进入顺序、在地化证据生成，并优化製造地，以满足当地的监管和商业性要求。

如何透过协作、拓展应用领域和提升生产韧性，将製药、医疗设备和数位化解决方案策略融合起来，从而创造临床和商业性价值

在周边动脉疾病治疗领域，各公司正采取多元化的策略，涵盖渐进式创新、平台开发和策略联盟。生物製药公司着重研发差异化分子和兼具心血管获益的联合疗法，以改善肢体功能并降低全身动脉粥样硬化风险；而医疗设备製造商则专注于提升手术效率、输送性和耐用性，并投资于新型涂层、导管设计以及与药物治疗方案相辅相成的组合产品。

在整个产业中，製药公司与医疗设备製造商之间的合作日益普遍，从而能够提供整合手术流程和药物疗法的综合价值提案。此外，人们对数位疗法和远端监测的兴趣日益浓厚，推动了与软体和分析服务提供者的合作，以改善术后护理和病人参与。从企业策略角度来看，各公司在研发早期就优先考虑监管方面的应对措施，扩展临床终点以纳入功能和生活品质指标，并加强生产能力以降低关税和供应链风险。总而言之，这些努力体现了从单一疗法转向综合解决方案的趋势。

产业领导者可采取切实可行的策略重点，以加强供应链、扩大证据产生并整合数位化医疗，从而加速治疗方法推广和支付方接受度。

产业领导者必须采取果断行动，将科学进步和营运转型转化为永续的竞争优势。首先，各机构应加快产生多学科证据，将手术创新与长期心血管和肢体预后联繫起来，从而增强其对支付方和医疗系统的价值提案。其次，供应链多元化和区域化生产模式可以降低关税波动风险，并提高对临床医生需求的应对力。投资于模组化设备设计以及从多个地区采购关键零件将增强营运韧性。

此外，企业应整合数位化健康解决方案，以支援药物依从性、远端监测和復原路径，从而促进功能恢復并减少再入院率。儘早与监管机构和支付方接洽，并设计包含病患报告结果和卫生经济学终点的临床试验，将有助于企业做好报销准备。最后，制定反映产品亚型、适应症、临床环境和给药途径细分的有针对性的商业策略，将最大限度地提高市场渗透率。开发与门诊手术中心工作流程和医院采购惯例相契合的销售和临床教育项目，将加速新型治疗方法的应用。

我们采用方法严谨的方法，结合临床医师访谈、临床文献、监管分析和情境规划，来检验我们的策略见解和建议。

本研究整合了第一手和第二手研究，旨在对周边动脉疾病治疗领域进行稳健且可重复的评估。第一手研究包括对临床医生、医院采购人员、门诊手术中心管理人员和临床试验研究人员进行结构化访谈，以收集有关药物治疗方案和医疗设备工作流程的真实世界资讯。这些定性研究结果辅以对公共临床试验註册库、同侪审查文献、监管指导文件和卫生技术评估的分析，以确保临床和监管方面的严谨性。

此分析架构整合了多轴细分方法、供应链和关税风险情境规划，以及涵盖临床结果、支付方要求和商业化路径的主题三角验证。资料检验过程包括将访谈结果与已发表的治疗应用趋势和医疗设备认证历史进行交叉比对。最后，敏感性分析和专家评审完善了策略意义和建议，确保报告能够为寻求在不断发展的治疗领域中开展研发、商业化和营运的循证路径的决策者提供支援。

整合临床进展、供应链压力和策略要务，为周边动脉疾病相关人员确定近期优先事项。

周边动脉疾病的治疗处于不断发展的临床科学、不断变化的医疗环境和复杂的商业性压力交汇点。该领域的特点是血管内技术的显着进步、对降低全身风险的抗血栓策略的重新关注，以及对能够证明肢体持久保全和改善患者功能的证据日益增长的需求。这些发展是在区域监管差异和潜在的关税引发的供应链中断的背景下进行的，因此需要製造商和医疗服务提供者采取积极主动且全面的策略应对措施。

简而言之，相关人员，将最有能力应对未来几年的挑战。透过优先考虑多学科证据生成和适应性商业化模式，各机构可以将科学创新转化为持续的临床效益和商业性可行性。最终，这将为周边动脉疾病患者建构一个更具韧性、以患者为中心的治疗生态系统。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 针对严重肢体缺血患者血管生成路径的新兴基因疗法
  • 药物释放型球囊和支架在治疗週边动脉狭窄的应用日益广泛
  • 将数位监测设备整合到周边动脉疾病管理中，用于持续评估肢体灌注状态。
  • 扩大新型口服抗血栓药物的使用范围，以减少血管再阻塞并改善长期通畅性
  • 用于膝下血管重建手术的组织工程血管移植物的最新进展
  • 扩大旨在抑制周边动脉疾病（PAD）中发炎介质的单株抗体的临床开发平臺
  • 实施远端医疗平台以进行远距运动疗法和患者依从性监测
  • 越来越关注利用基于生物标记的PAD患者亚型分层进行个人化医疗

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型周边动脉疾病治疗市场

  • 抗凝血剂
    • 口服抗凝血剂
    • 肝素
    • Warfarin
  • 抗血小板药物
    • 阿斯匹灵
    • Clopidogrel
    • 替格瑞洛
  • 溶栓剂
    • 组织型胞浆素原原激活剂
    • 尿激酶
  • 血管扩张剂
    • Cilostazol
    • Pentoxifylline

第九章周边动脉疾病药物市场（依适应症划分）

  • 严重肢体缺血
  • 间歇性跛行

第十章周边动脉疾病治疗市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十一章周边动脉疾病治疗药物市场（依给药途径划分）

  • 口服
  • 肠外

第十二章 各地区周边动脉疾病治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章周边动脉疾病治疗市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国周边动脉疾病治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • Johnson & Johnson
    • Becton, Dickinson and Company
    • Koninklijke Philips NV
    • Cardiovascular Systems, Inc.
    • Merit Medical Systems, Inc.
    • Teleflex Incorporated
Product Code: MRR-69324464D29D

The Peripheral Arterial Disease Therapeutics Market is projected to grow by USD 10.30 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.14 billion
Estimated Year [2025] USD 5.60 billion
Forecast Year [2032] USD 10.30 billion
CAGR (%) 9.06%

An integrated overview of peripheral arterial disease therapeutics that frames clinical, operational, and commercial drivers shaping treatment pathways and stakeholder decisions

Peripheral arterial disease represents a complex intersection of vascular pathology, therapeutic innovation, and shifting care delivery models. This executive summary synthesizes multidisciplinary evidence to illuminate where clinical practice, regulatory environments, and commercial strategy converge. The narrative that follows focuses on therapeutic modalities ranging from classical pharmacotherapies to device-based interventions, and frames these developments against the backdrop of health system priorities and patient-centric outcomes.

The clinical burden of limb ischemia and intermittent claudication continues to drive demand for both established agents and next-generation therapeutics. Consequently, clinicians and payers increasingly evaluate interventions on procedural efficacy, long-term limb salvage, and cardiovascular risk reduction. Moreover, the patient journey now commonly involves outpatient pathways, integrated wound care, and coordinated vascular teams that emphasize functional recovery alongside survival metrics. Given these realities, stakeholders must integrate clinical evidence with operational feasibility and evolving reimbursement paradigms to optimize therapeutic adoption and patient outcomes.

How procedural innovation, pharmacologic evolution, and digital care pathways are jointly redefining standards of treatment and long-term management for peripheral arterial disease

Clinical practice and technology are converging to create transformative shifts in how peripheral arterial disease is diagnosed, treated, and managed. In recent years, minimally invasive endovascular techniques have advanced rapidly, supported by improvements in imaging, catheter technologies, and adjunctive devices. These procedural advances have coincided with a renewed focus on pharmacologic strategies that extend beyond symptom relief to reduce major adverse cardiovascular events, thereby reframing therapeutic objectives across care settings.

Concurrently, digital health and remote monitoring are changing post-procedural follow-up and chronic disease management. Telemedicine-facilitated vascular clinics and wearable-enabled gait and perfusion monitoring complement traditional vascular labs, enabling earlier detection of deterioration and tailored rehabilitation programs. At the same time, regenerative medicine and targeted biologics continue to progress through clinical development, promising alternative pathways for patients with limited revascularization options. Finally, care delivery has shifted toward ambulatory settings for selected procedures, increasing the strategic importance of ambulatory surgical centers and specialty clinics as sites of care. Together, these factors are driving integrated care models that prioritize value, patient experience, and longitudinal outcomes.

Anticipating supply chain adjustments, procurement strategies, and product design shifts as U S tariff changes in 2025 reshape cost dynamics and operational resilience in the therapeutic ecosystem

Changes in U.S. tariff policy projected for 2025 have the potential to affect multiple elements of the peripheral arterial disease therapeutic ecosystem, and stakeholders are already preparing for varied ripple effects. Tariffs on imported medical devices, pharmaceuticals, and intermediate components may increase landed costs for devices such as specialized catheters, drug-coated balloons, and diagnostic imaging equipment. As a result, manufacturers and health systems may reassess sourcing strategies, seeking to mitigate exposure through alternative suppliers, nearshoring, or accelerated localization of production.

Moreover, tariffs can influence the supply chain timing and inventory strategies adopted by hospitals and ambulatory surgical centers. In the near term, purchasing teams may expand buffer inventories or renegotiate supply contracts to stabilize access to critical consumables. Over time, manufacturers could revise pricing models or shift manufacturing footprints, which in turn would affect procurement cycles and capital planning for facility upgrades. From a research and development perspective, tariff-driven cost pressures may reorient investment priorities toward cost-efficient innovations and modular device designs that rely less on tariff-exposed components. Finally, regulatory and payer responses may evolve to address affordability and access, prompting collaborative initiatives to preserve continuity of care without compromising clinical standards.

Strategic segmentation insights that integrate product subclasses, clinical indications, care delivery channels, and administration routes to inform development and commercialization choices

A granular understanding of patient, product, and channel segmentation is essential to align research, development, and commercialization strategies. Product type considerations span anticoagulants, antiplatelet agents, thrombolytics, and vasodilators, with anticoagulants subdividing into direct oral anticoagulants, heparin, and warfarin while antiplatelet agents encompass aspirin, clopidogrel, and ticagrelor; thrombolytics include tissue plasminogen activator and urokinase, and vasodilators are typified by cilostazol and pentoxifylline. These distinctions influence clinical decision-making, formulary placement, and post-procedural management, since each subclass carries unique pharmacodynamics, monitoring requirements, and interaction profiles.

Indication-based segmentation discriminates between critical limb ischemia and intermittent claudication, which differ markedly in disease trajectory, therapeutic urgency, and multidisciplinary care needs. End-user channels range from ambulatory surgical centers to hospitals and specialty clinics, and the choice of setting impacts device selection, staffing models, reimbursement pathways, and length of stay. Finally, route of administration - oral versus parenteral - intersects with adherence considerations, outpatient feasibility, and resource allocation for monitoring and administration. By integrating these segmentation axes, stakeholders can prioritize clinical development programs, tailor marketing messages, and design access strategies that address the nuanced needs of clinicians, payers, and patients.

Regional contours and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate regulatory approaches, evidence needs, and access strategies

Regional dynamics exert a powerful influence on clinical practice, regulatory expectations, and supply chain architecture. In the Americas, clinical guidelines increasingly emphasize integrated cardiovascular risk reduction alongside limb-focused interventions, while health systems balance specialist capacity with growing outpatient procedural volumes. This region also exhibits significant heterogeneity in payer models, which affects formulary access and adoption timelines for novel therapies. Consequently, strategies that prioritize real-world evidence generation and payer-centric health economic dossiers will find traction in commercial conversations.

Across Europe, Middle East & Africa, regulatory harmonization and varying reimbursement pathways shape market entry strategies and clinical adoption rates. In many markets, authorities place a premium on long-term outcomes and cost-effectiveness data, which can lengthen time to wide adoption but also create durable value propositions for therapies that demonstrate limb salvage and cardiovascular benefit. In contrast, Asia-Pacific markets are characterized by rapid uptake of minimally invasive procedures, expanding interventional capacity, and strong domestic manufacturing ambitions, which together influence pricing dynamics and partnership models. Recognizing these regional contours allows sponsors to sequence market entry, localize evidence generation, and optimize manufacturing footprints to meet distinct regulatory and commercial requirements.

How pharmaceutical, medical device, and digital solution strategies are converging through partnerships, expanded endpoints, and manufacturing resilience to capture clinical and commercial value

Companies operating in the peripheral arterial disease therapeutic space are pursuing diversified strategies that span incremental innovation, platform development, and strategic partnerships. Biopharmaceutical firms emphasize differentiated molecules and composite cardiovascular benefit profiles that address both limb outcomes and systemic atherosclerotic risk. At the same time, medical device manufacturers focus on procedural efficiency, deliverability, and durability, investing in novel coatings, catheter design, and combination products that complement pharmacologic regimens.

Across the industry, collaboration between pharma and device players is increasingly common, enabling bundled value propositions that align procedural and medical management. Additionally, growing interest in digital therapeutics and remote monitoring has catalyzed partnerships with software and analytics providers to enhance post-procedural care and patient engagement. From a corporate strategy perspective, companies are prioritizing regulatory alignment early in development, expanding clinical endpoints to include functional and quality-of-life measures, and pursuing manufacturing resilience to mitigate tariff and supply chain risks. These approaches collectively reflect a shift toward holistic solutions that extend beyond single-modality interventions.

Actionable strategic priorities for industry leaders to fortify supply chains, amplify evidence generation, and integrate digital care to accelerate therapy adoption and payer acceptance

Industry leaders must act decisively to convert scientific advances and operational shifts into sustainable competitive advantage. First, organizations should accelerate cross-disciplinary evidence generation that links procedural innovation with long-term cardiovascular and limb outcomes, thereby strengthening value propositions for payers and health systems. Secondly, supply chain diversification and regional manufacturing options will reduce exposure to tariff volatility and improve responsiveness to clinician demand. Investing in modular device designs and procuring critical components from multiple geographies will enhance operational resilience.

Furthermore, companies should integrate digital health solutions to support adherence, remote monitoring, and rehabilitation pathways that improve functional recovery and reduce readmissions. Engaging regulators and payers early, and designing trials that incorporate patient-reported outcomes and health economic endpoints, will facilitate reimbursement readiness. Finally, targeted commercial strategies that reflect segmentation across product subtypes, indications, care settings, and routes of administration will maximize uptake; aligning sales and clinical education programs to ambulatory surgical center workflows and hospital procurement practices will accelerate diffusion of novel therapies.

A methodologically rigorous approach combining clinician interviews, clinical literature, regulatory analysis, and scenario planning to validate strategic insights and recommendations

This research synthesizes primary and secondary sources to deliver a robust, reproducible assessment of the peripheral arterial disease therapeutics landscape. Primary research included structured interviews with clinicians, hospital procurement leaders, ambulatory surgical center administrators, and clinical trial investigators to capture frontline experiences with pharmacologic regimens and device workflows. These qualitative insights were supplemented with analyses of publicly available clinical trial registries, peer-reviewed literature, regulatory guidance documents, and health technology assessments to ensure clinical and regulatory rigor.

The analytical framework incorporates a multi-axis segmentation approach, scenario planning for supply chain and tariff exposures, and thematic triangulation across clinical outcomes, payer requirements, and commercial pathways. Data validation processes involved cross-referencing interview findings with published procedure utilization trends and device approval histories. Finally, sensitivity checks and expert reviews helped refine strategic implications and recommendations, ensuring the report supports decision-makers seeking evidence-based pathways for development, commercialization, and operations within this evolving therapeutic area.

Synthesis of clinical advances, supply chain pressures, and strategic imperatives that together define the near-term priorities for peripheral arterial disease stakeholders

Peripheral arterial disease therapeutics sits at the intersection of evolving clinical science, changing care settings, and complex commercial pressures. The landscape is characterized by meaningful advances in endovascular technology, renewed emphasis on antithrombotic strategies that reduce systemic risk, and increasing demand for evidence that demonstrates durable limb salvage and improved patient function. These developments occur against a backdrop of regional regulatory diversity and potential tariff-driven supply chain disruptions, which together require proactive and integrated strategic responses from manufacturers and providers.

In sum, stakeholders that align product development with payer evidence needs, invest in supply chain agility, and leverage digital care to enhance outcomes will be best positioned to navigate the coming years. By prioritizing multidisciplinary evidence generation and adaptive commercialization models, organizations can translate scientific innovation into sustained clinical benefit and commercial viability. The result will be a more resilient, patient-centered therapeutic ecosystem for individuals living with peripheral arterial disease.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of gene therapy targeting angiogenesis pathways in critical limb ischemia patients
  • 5.2. Rising adoption of drug-coated balloons and stents in peripheral arterial stenosis interventions
  • 5.3. Integration of digital monitoring devices for continuous limb perfusion assessment in PAD management
  • 5.4. Expansion of novel oral antithrombotic agents to reduce restenosis and improve long-term patency
  • 5.5. Advances in tissue-engineered vascular grafts for below-the-knee revascularization procedures
  • 5.6. Growing clinical pipeline of monoclonal antibodies aimed at inhibiting inflammatory mediators in PAD
  • 5.7. Implementation of telehealth platforms for remote exercise therapy and patient adherence monitoring
  • 5.8. Increasing focus on personalized medicine using biomarker-driven stratification of PAD patient subtypes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Peripheral Arterial Disease Therapeutics Market, by Product Type

  • 8.1. Anticoagulants
    • 8.1.1. Direct Oral Anticoagulants
    • 8.1.2. Heparin
    • 8.1.3. Warfarin
  • 8.2. Antiplatelet Agents
    • 8.2.1. Aspirin
    • 8.2.2. Clopidogrel
    • 8.2.3. Ticagrelor
  • 8.3. Thrombolytics
    • 8.3.1. Tissue Plasminogen Activator
    • 8.3.2. Urokinase
  • 8.4. Vasodilators
    • 8.4.1. Cilostazol
    • 8.4.2. Pentoxifylline

9. Peripheral Arterial Disease Therapeutics Market, by Indication

  • 9.1. Critical Limb Ischemia
  • 9.2. Intermittent Claudication

10. Peripheral Arterial Disease Therapeutics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Peripheral Arterial Disease Therapeutics Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Peripheral Arterial Disease Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Peripheral Arterial Disease Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Peripheral Arterial Disease Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. Boston Scientific Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Terumo Corporation
    • 15.3.5. Johnson & Johnson
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Koninklijke Philips N.V.
    • 15.3.8. Cardiovascular Systems, Inc.
    • 15.3.9. Merit Medical Systems, Inc.
    • 15.3.10. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY DIRECT ORAL ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HEPARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY WARFARIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASPIRIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CLOPIDOGREL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TICAGRELOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY UROKINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CILOSTAZOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PENTOXIFYLLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY CRITICAL LIMB ISCHEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INTERMITTENT CLAUDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANTS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY VASODILATORS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2